India, Nov. 20 -- Friday, Aprea Therapeutics, Inc. (APRE) announced updated interim results from its ongoing Phase 1 ACESOT-1051 trial evaluating APR-1051, an investigational oral WEE1 inhibitor, in patients with advanced solid tumors. The findings were presented at the 38th EORTC-NCI-AACR Symposium in Barcelona, Spain.

As of the November 1, 2026 data cutoff, 56 patients had received APR-1051 across multiple dose levels, with 43 evaluable for tumor response. Two patients with PPP2R1A-mutated uterine cancers achieved partial responses, including one confirmed response that remained ongoing after more than 10 months of treatment. Sixteen patients achieved stable disease, with five maintaining it for at least four months.

Pharmacodynamic tes...